Back to Search
Start Over
Effects of Oral Anticoagulants on Patients With Atrial Fibrillation Aged 90 Years and Older: Comparison Among Direct Oral Anticoagulant, Warfarin Anticoagulant, and Nonanticoagulation
- Source :
- Journal of cardiovascular pharmacology. 74(3)
- Publication Year :
- 2019
-
Abstract
- This study aimed to investigate the effects of anticoagulants on ultra-aged patients with nonvalvular atrial fibrillation (AF). We retrospectively studied 320 consecutive patients with AF (median age, 91 years; range 90-100.1 years). Patients were categorized as follows: patients taking direct oral anticoagulant (DOAC group, n = 93), those taking warfarin (warfarin group, n = 147), and those not taking oral anticoagulants (non-OAC group, n = 80). During the follow-up periods (median 3.00 years; first and fourth quantiles, 1.13 and 4.56 years, respectively), in thromboembolic events, the DOAC, warfarin, and non-OAC groups showed the lowest (0%, 0/93; 0%/year), intermediate (4.7%, 7/149; 1.43%/year), and highest (5%, 4/80; 2.65%/year) incidence rates, respectively. In major bleeding events, the DOAC, warfarin, and non-OAC groups showed the highest (9.67%, 9/96; 5.00%/year), intermediate (8.1%, 12/149; 2.46%/year), and lowest (0%, 0/80; 0%/year) incidence rates, respectively. These differences in the relationships of the 3 groups were statistically significant. Confounding factors did not affect these results. Bruises associated with impairment of motor function with aging caused major bleeding in approximately 60% of major bleeding cases. The Cox proportional hazards model revealed that warfarin decreased mortality, whereas antiplatelet drugs increased mortality. In conclusion, DOACs had considerably high incidence of major bleeding events, whereas absence of OAC treatment was associated with substantially high thromboembolic events. Warfarin showed acceptable incidence ratios of both events. At present, warfarin is thus believed to be adequate for ultra-aged (≥90 years) patients with nonvalvular AF. Avoidance of bruises was important to prevent major bleeding events. Antiplatelet drugs were suggested not to be adequate for these patients.
- Subjects :
- 0301 basic medicine
Male
medicine.medical_specialty
Time Factors
medicine.drug_class
Clinical Decision-Making
Administration, Oral
Hemorrhage
030204 cardiovascular system & hematology
Risk Assessment
Antithrombins
03 medical and health sciences
0302 clinical medicine
Risk Factors
Internal medicine
Atrial Fibrillation
medicine
Humans
Retrospective Studies
Pharmacology
Aged, 80 and over
Proportional hazards model
business.industry
Incidence (epidemiology)
Incidence
Patient Selection
Confounding
Anticoagulant
Warfarin
Age Factors
Anticoagulants
Atrial fibrillation
Retrospective cohort study
medicine.disease
Stroke
030104 developmental biology
Treatment Outcome
Embolism
Female
Cardiology and Cardiovascular Medicine
business
medicine.drug
Subjects
Details
- ISSN :
- 15334023
- Volume :
- 74
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Journal of cardiovascular pharmacology
- Accession number :
- edsair.doi.dedup.....f1a86d446027ae0aa5176d3bd6dd543a